BACKGROUND: Urinary liver-type fatty acid-binding protein (L-FABP) is a proximal tubular injury candidate biomarker for early detection of acute kidney injury (AKI), with variable performance characteristics depending on clinical settings. STUDY DESIGN: Meta-analysis of diagnostic test studies assessing the performance of urinary L-FABP in AKI. SETTING & POPULATION: Literature search in MEDLINE, EMBASE, Scopus, Google Scholar, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov using search terms "liver-type fatty acid-binding protein" and "L-FABP." SELECTION CRITERIA FOR STUDIES: Studies of humans investigating the performance characteristics of urinary L-FABP for the early diagnosis of AKI and AKI-related outcomes, including dialysis requirement and mortality. PREDICTOR: Urinary L-FABP. OUTCOMES: Diagnosis of AKI, dialysis requirement, and in-hospital death. RESULTS: 15 prospective cohort and 2 case-control studies were identified. Only 7 cohort studies could be meta-analyzed. The estimated sensitivity of urinary L-FABP level for the diagnosis of AKI was 74.5% (95% CI, 60.4%-84.8%), and specificity was 77.6% (95% CI, 61.5%-88.2%). The estimated sensitivity of urinary L-FABP level for predicting dialysis requirement was 69.1% (95% CI, 34.6%-90.5%), and specificity was 42.7% (95% CI, 3.1%-94.5%); for in-hospital mortality, sensitivity and specificity were 93.2% (95% CI, 66.2%-99.0%) and 78.8% (95% CI, 27.0%-97.4%), respectively. LIMITATIONS: Paucity and low quality of studies, different clinical settings, and variable definitions of AKI. CONCLUSIONS: Although urinary L-FABP may be a promising biomarker for early detection of AKI and prediction of dialysis requirement and in-hospital mortality, its potential value needs to be validated in large studies and across a broader spectrum of clinical settings.
BACKGROUND: Urinary liver-type fatty acid-binding protein (L-FABP) is a proximal tubular injury candidate biomarker for early detection of acute kidney injury (AKI), with variable performance characteristics depending on clinical settings. STUDY DESIGN: Meta-analysis of diagnostic test studies assessing the performance of urinary L-FABP in AKI. SETTING & POPULATION: Literature search in MEDLINE, EMBASE, Scopus, Google Scholar, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov using search terms "liver-type fatty acid-binding protein" and "L-FABP." SELECTION CRITERIA FOR STUDIES: Studies of humans investigating the performance characteristics of urinary L-FABP for the early diagnosis of AKI and AKI-related outcomes, including dialysis requirement and mortality. PREDICTOR: Urinary L-FABP. OUTCOMES: Diagnosis of AKI, dialysis requirement, and in-hospital death. RESULTS: 15 prospective cohort and 2 case-control studies were identified. Only 7 cohort studies could be meta-analyzed. The estimated sensitivity of urinary L-FABP level for the diagnosis of AKI was 74.5% (95% CI, 60.4%-84.8%), and specificity was 77.6% (95% CI, 61.5%-88.2%). The estimated sensitivity of urinary L-FABP level for predicting dialysis requirement was 69.1% (95% CI, 34.6%-90.5%), and specificity was 42.7% (95% CI, 3.1%-94.5%); for in-hospital mortality, sensitivity and specificity were 93.2% (95% CI, 66.2%-99.0%) and 78.8% (95% CI, 27.0%-97.4%), respectively. LIMITATIONS: Paucity and low quality of studies, different clinical settings, and variable definitions of AKI. CONCLUSIONS: Although urinary L-FABP may be a promising biomarker for early detection of AKI and prediction of dialysis requirement and in-hospital mortality, its potential value needs to be validated in large studies and across a broader spectrum of clinical settings.
Authors: Julia M Hofstra; Jeroen K J Deegens; Eric J Steenbergen; Jack F M Wetzels Journal: Nephrol Dial Transplant Date: 2008-04-10 Impact factor: 5.992
Authors: Orfeas Liangos; Ron Wald; John W O'Bell; Lorilyn Price; Brian J Pereira; Bertrand L Jaber Journal: Clin J Am Soc Nephrol Date: 2005-10-26 Impact factor: 8.237
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Isidro Torregrosa; Carmina Montoliu; Amparo Urios; María Jesús Andrés-Costa; Carla Giménez-Garzó; Isabel Juan; María Jesús Puchades; María Luisa Blasco; Arturo Carratalá; Rafael Sanjuán; Alfonso Miguel Journal: Heart Vessels Date: 2014-07-03 Impact factor: 2.037
Authors: Michael R Bennett; Edward Nehus; Christopher Haffner; Qing Ma; Prasad Devarajan Journal: Pediatr Nephrol Date: 2014-10-28 Impact factor: 3.714
Authors: Marianne Schmid; Deepansh Dalela; Rana Tahbaz; Jessica Langetepe; Marco Randazzo; Roland Dahlem; Margit Fisch; Quoc-Dien Trinh; Felix K-H Chun Journal: World J Nephrol Date: 2015-05-06
Authors: Anitha Vijayan; Sarah Faubel; David J Askenazi; Jorge Cerda; William H Fissell; Michael Heung; Benjamin D Humphreys; Jay L Koyner; Kathleen D Liu; Girish Mour; Thomas D Nolin; Azra Bihorac Journal: Am J Kidney Dis Date: 2016-03-04 Impact factor: 8.860